Armata Pharmaceuticals Inc (ARMP)

$10.18 -0.38 (-3.60%)
Market Cap 372.92M
Revenue (ttm) 4.90M
Net Income (ttm) -173.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,546.94%
Debt to Equity Ratio -0.47
Volume 22,900
Avg Vol 41,338
Day's Range N/A - N/A
Shares Out 36.63M
Stochastic %K 79%
Beta 1.38
Analysts Strong Sell
Price Target $15.00

Company Profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 665 2928
Fax: 310 665 2963
Address:
5005 McConnell Avenue, Los Angeles, United States
focafoca99
focafoca99 Apr. 3 at 8:44 PM
$ARMP set its 2026 annual meeting for June 11, with April 17 as the record date and the usual proposal deadline reset because the meeting timing changed.
0 · Reply
Trapped
Trapped Mar. 31 at 5:33 PM
$ARMP phase 3 starting. let’s go!
0 · Reply
0_oooo
0_oooo Mar. 31 at 3:41 PM
$ARMP 🙃🙄
0 · Reply
Few_erish
Few_erish Mar. 26 at 6:57 PM
$ARMP this thing woke up
1 · Reply
Few_erish
Few_erish Mar. 25 at 4:29 PM
$ARMP watch the tape
1 · Reply
Trapped
Trapped Mar. 23 at 11:35 AM
$ARMP power up!! let’s go
0 · Reply
Alex036
Alex036 Mar. 20 at 2:19 PM
$ARMP Lesson #3 completed.Waiting for the next one.
2 · Reply
DragonAlgo
DragonAlgo Mar. 20 at 10:29 AM
🐉 $ARMP PUT — DragonAlgo® Signal Contract: ARMP PUT Expiry: 2026-08-21 | Strike: $7.50 | Type: PUT Option Plan (premium): Entry: $1.50 Stop: $1.08 TP1: $1.95 TP2: $2.55 TP3: $3.60 🔗 https://dragonalgo.com
1 · Reply
Trapped
Trapped Mar. 17 at 12:42 PM
$ARMP undervalued for sure
0 · Reply
DragonAlgo
DragonAlgo Mar. 17 at 5:03 AM
🐉 $ARMP PUT — DragonAlgo® Signal Contract: ARMP PUT Expiry: 2026-08-21 | Strike: $7.50 | Type: PUT Option Plan (premium): Entry: $1.50 Stop: $1.08 TP1: $1.95 TP2: $2.55 TP3: $3.60 System-defined risk profile. 🔗 https://dragonalgo.com
0 · Reply
Latest News on ARMP
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results

Mar 25, 2026, 4:05 PM EDT - 10 days ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results

ARMP

Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update

Mar 19, 2026, 7:00 AM EDT - 17 days ago

Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update

ARMP

Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02

Feb 23, 2026, 7:00 AM EST - 5 weeks ago

Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02

ARMP

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

Jan 13, 2026, 7:00 AM EST - 2 months ago

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

ARMP

Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

Nov 18, 2025, 7:00 AM EST - 4 months ago

Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

ARMP

Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

Nov 12, 2025, 4:05 PM EST - 5 months ago

Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

ARMP

Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

Nov 10, 2025, 7:00 AM EST - 5 months ago

Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

ARMP

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™

Oct 22, 2025, 11:10 AM EDT - 5 months ago

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™

ARMP

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™

Oct 14, 2025, 7:00 AM EDT - 6 months ago

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™

ARMP

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Sep 8, 2025, 7:00 AM EDT - 7 months ago

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

ARMP

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:00 AM EDT - 7 months ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

ARMP

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Aug 12, 2025, 4:05 PM EDT - 8 months ago

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

ARMP

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

May 19, 2025, 7:00 AM EDT - 11 months ago

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

ARMP

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 11 months ago

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

ARMP

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

May 1, 2025, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

ARMP

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

Mar 20, 2025, 5:56 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

ARMP

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

Mar 12, 2025, 5:08 PM EDT - 1 year ago

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

ARMP INVA

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

ARMP

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Dec 19, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

ARMP

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Nov 19, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

ARMP

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update

Nov 13, 2024, 4:05 PM EST - 1 year ago

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update

ARMP

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

Nov 12, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

ARMP

Armata Pharmaceuticals Announces Structural Biology Publication

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Structural Biology Publication

ARMP

Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

ARMP

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

Aug 26, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

ARMP

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

Aug 15, 2024, 4:45 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

ARMP

Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update

ARMP

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

ARMP

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

ARMP

Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024

Jul 10, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024

ARMP

Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update

May 7, 2024, 4:01 PM EDT - 2 years ago

Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update

ARMP

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

Mar 21, 2024, 4:05 PM EDT - 2 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

ARMP

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

Mar 4, 2024, 4:01 PM EST - 2 years ago

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

ARMP INVA

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

Feb 21, 2024, 7:00 AM EST - 2 years ago

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

ARMP

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

Nov 14, 2023, 4:00 PM EST - 2 years ago

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

ARMP

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

ARMP

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

ARMP

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

ARMP

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

ARMP

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

ARMP

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

May 31, 2023, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

ARMP

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

May 11, 2023, 4:05 PM EDT - 3 years ago

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

ARMP

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

Mar 16, 2023, 4:10 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

ARMP

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

Mar 6, 2023, 6:00 AM EST - 3 years ago

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

ARMP

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

Jan 10, 2023, 4:05 PM EST - 3 years ago

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

ARMP INVA

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Dec 22, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

ARMP

Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

Nov 28, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

ARMP

Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update

Nov 9, 2022, 4:15 PM EST - 3 years ago

Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update

ARMP

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

ARMP

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

Aug 1, 2022, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

ARMP

focafoca99
focafoca99 Apr. 3 at 8:44 PM
$ARMP set its 2026 annual meeting for June 11, with April 17 as the record date and the usual proposal deadline reset because the meeting timing changed.
0 · Reply
Trapped
Trapped Mar. 31 at 5:33 PM
$ARMP phase 3 starting. let’s go!
0 · Reply
0_oooo
0_oooo Mar. 31 at 3:41 PM
$ARMP 🙃🙄
0 · Reply
Few_erish
Few_erish Mar. 26 at 6:57 PM
$ARMP this thing woke up
1 · Reply
Few_erish
Few_erish Mar. 25 at 4:29 PM
$ARMP watch the tape
1 · Reply
Trapped
Trapped Mar. 23 at 11:35 AM
$ARMP power up!! let’s go
0 · Reply
Alex036
Alex036 Mar. 20 at 2:19 PM
$ARMP Lesson #3 completed.Waiting for the next one.
2 · Reply
DragonAlgo
DragonAlgo Mar. 20 at 10:29 AM
🐉 $ARMP PUT — DragonAlgo® Signal Contract: ARMP PUT Expiry: 2026-08-21 | Strike: $7.50 | Type: PUT Option Plan (premium): Entry: $1.50 Stop: $1.08 TP1: $1.95 TP2: $2.55 TP3: $3.60 🔗 https://dragonalgo.com
1 · Reply
Trapped
Trapped Mar. 17 at 12:42 PM
$ARMP undervalued for sure
0 · Reply
DragonAlgo
DragonAlgo Mar. 17 at 5:03 AM
🐉 $ARMP PUT — DragonAlgo® Signal Contract: ARMP PUT Expiry: 2026-08-21 | Strike: $7.50 | Type: PUT Option Plan (premium): Entry: $1.50 Stop: $1.08 TP1: $1.95 TP2: $2.55 TP3: $3.60 System-defined risk profile. 🔗 https://dragonalgo.com
0 · Reply
Trapped
Trapped Mar. 13 at 5:31 PM
$ARMP 15 coming
0 · Reply
DragonAlgo
DragonAlgo Mar. 13 at 10:26 AM
🐉 $ARMP PUT — DragonAlgo® Signal Contract: ARMP PUT Expiry: 2026-08-21 | Strike: $7.50 | Type: PUT Option Plan (premium): Entry: $1.50 Stop: $1.08 TP1: $1.95 TP2: $2.55 TP3: $3.60 🔗 https://dragonalgo.com
1 · Reply
SuperGreenToday
SuperGreenToday Mar. 11 at 9:34 PM
$ARMP Share Price: $11.43 Contract Selected: Aug 21, 2026 $10 Calls Buy Zone: $0.51 – $0.63 Target Zone: $0.91 – $1.11 Potential Upside: 68% ROI Time to Expiration: 162 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Trapped
Trapped Mar. 10 at 12:09 AM
$ARMP 56k shares traded and it’s up $1 plus. this is going to explode with proper FDA. news …hold on
0 · Reply
Trapped
Trapped Mar. 8 at 6:26 PM
$ARMP Armata Pharmaceuticals, Inc. : H.C. Wainwright raises target to $15 from $9 *
0 · Reply
Trapped
Trapped Mar. 4 at 2:07 PM
$ARMP any good news from FDA will ramp up this stock big time. buy and hold your positions. best way
0 · Reply
History101
History101 Mar. 2 at 8:53 PM
$ARMP a big day for me, my ARMP position is now up over 100%...awesome. GLTALs!!
1 · Reply
Trapped
Trapped Mar. 2 at 3:32 PM
$ARMP $15 this month
0 · Reply
Alex036
Alex036 Feb. 26 at 4:38 PM
$ARMP This train is not intended for regular passengers (ordinary SHs), but only for train owners (MMs). Once MMs achieve their personal ultimate goals, they will kick everyone off the train.
1 · Reply
Trapped
Trapped Feb. 26 at 4:02 PM
$ARMP the stock is worth a lot more … bottom line
0 · Reply
Watchingnow
Watchingnow Feb. 26 at 1:26 PM
$ARMP FDA news means what exactly? Its obviously not the go ahead to market the drug. Forgive the ignorance. Is this a first step in accelerated approval? Whats the new timeline? Thanks
0 · Reply
Trapped
Trapped Feb. 25 at 5:59 PM
$ARMP so we are currently at 439 million market cap. hmmmm what would be a main stream drug with today in annual sales?? 1/2 billion. you can do the math. that’s 5 x the pps. hello $50.
0 · Reply